Modality
Fusion Protein
MOA
WRNi
Target
DLL3
Pathway
Ferroptosis
Endometrial CaCholangiocarcinomaADHD
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
~Dec 2018
→ ~Mar 2020
Phase 2
Jun 2020
→ Jul 2029
Phase 2Current
NCT05154906
2,791 pts·Endometrial Ca
2020-06→TBD·Terminated
NCT08049877
2,343 pts·Cholangiocarcinoma
2025-03→2029-07·Recruiting
5,134 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-206mo agoPh1 Dose Esc· Endometrial Ca
2029-07-133.3y awayPh3 Readout· Cholangiocarcinoma
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2/3
Termina…
P2/3
Recruit…
Catalysts
Ph1 Dose Esc
2025-09-20 · 6mo ago
Endometrial Ca
Ph3 Readout
2029-07-13 · 3.3y away
Cholangiocarcinoma
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05154906 | Phase 2/3 | Endometrial Ca | Terminated | 2791 | HbA1c |
| NCT08049877 | Phase 2/3 | Cholangiocarcinoma | Recruiting | 2343 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| REG-7737 | Regeneron | Preclinical | CD123 |